 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 April 2002 | Volume 136 Issue 8 | Pages 604-615
Progression to renal parenchymal damage and end-stage renal disease, which seems to be largely independent of the initial insult, is the final common pathway for chronic, proteinuric nephropathies in animals and humans. The key event is enhanced glomerular capillary pressure; this impairs glomerular permeability to proteins and permits excessive amounts of proteins to reach the lumen of the proximal tubule. The secondary process of reabsorption of filtered proteins can contribute to renal interstitial injury by activating intracellular events, including upregulation of the genes encoding vasoactive and inflammatory mediators. Both interstitial inflammation and progression of disease can be controlled by such drugs as angiotensin-converting enzyme inhibitors, which strengthen the glomerular permeability barrier to proteins and thereby limit proteinuria and filtered protein-dependent inflammatory signals. Clinical data strongly suggest that remission can now be achieved in some patients with chronic renal disease. Because of the current lag time between starting treatment and remission, however, a substantial proportion of patients still progress to end-stage renal disease before renal function begins to stabilize. A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most patients with proteinuric nephropathies.
Author and Article Information
From Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Requests for Single Reprints: Giuseppe Remuzzi, MD, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy; e-mail, gremuzzi{at}marionegri.it.
Current Author Addresses: Drs. Remuzzi, Ruggenenti, and Perico: Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. REVIEW
Series in Primary Care Internal Medicine
Chronic Renal Diseases: Renoprotective Benefits of Renin–Angiotensin System Inhibition
This article has been cited by other articles:
|
|
 |
|
  I. Navarro, R. Poveda, J. Torras, A. M. Castelao, and J. M. Grinyo Acute renal failure associated to renin angiotensin system (RAS) inhibitors its burden in a nephrology department Nephrol. Dial. Transplant., January 1, 2008; 23(1): 413 - 414. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Palm, M. L. Onozato, Z. Luo, and C. S. Wilcox Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3227 - H3245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ardissino, S. Vigano, S. Testa, V. Dacco, F. Paglialonga, A. Leoni, M. Belingheri, L. Avolio, A. Ciofani, A. Claris-Appiani, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy report from the ItalKid Project database Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2525 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Spruill, W. E. Wade, and H. H. Cobb III Estimating glomerular filtration rate with a modification of diet in renal disease equation: Implications for pharmacy Am. J. Health Syst. Pharm., March 15, 2007; 64(6): 652 - 660. [Full Text] [PDF]
|
|
|
|
 |
|
 W. E Wade and W. J Spruill New Serum Creatinine Assay Standardization: Implications for Drug Dosing Ann. Pharmacother., March 1, 2007; 41(3): 475 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Blix, K. K. Viktil, T. A. Moger, and A. Reikvam Use of renal risk drugs in hospitalized patients with impaired renal function--an underestimated problem? Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3164 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.C. Edwards, R.P. Steeds, C.J. Ferro, and J.N. Townend The treatment of coronary artery disease in patients with chronic kidney disease QJM, November 1, 2006; 99(11): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stevens, T. Greene, and A. S. Levey Surrogate End Points for Clinical Trials of Kidney Disease Progression Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 874 - 884. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Okada, T. Kikuta, T. Inoue, Y. Kanno, S. Ban, T. Sugaya, M. Takigawa, and H. Suzuki Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner Am. J. Pathol., March 1, 2006; 168(3): 737 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D Stevanovic, D. A Price, M C. Lansang, N. D. Fisher, L. M. Laffel, and N. K Hollenberg Renin Release in Response to Renin System Blockade: Activation of the Renin System in Type 1 Diabetes Mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 78 - 83. [Abstract] [PDF]
|
|
|
|
|
|
Y. Kanno, H. Okada, Y. Yamaji, Y. Nakazato, and H. Suzuki Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation QJM, March 1, 2005; 98(3): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chiurchiu, G. Remuzzi, and P. Ruggenenti Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Segura, J. A. Garcia-Donaire, and L. M. Ruilope Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S64 - S66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Neumann, R. Kain, H. Regele, A. Soleiman, S. Kandutsch, and F. T. Meisl Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis Nephrol. Dial. Transplant., January 1, 2005; 20(1): 96 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Long, K. L. Price, J. Herrera-Acosta, and R. J. Johnson How Does Angiotensin II Cause Renal Injury? Hypertension, April 1, 2004; 43(4): 722 - 723. [Full Text] [PDF]
|
|
|
|
|
|
T. Umekawa, Y. Hatanaka, T. Kurita, and S. R. Khan Effect of Angiotensin II Receptor Blockage on Osteopontin Expression and Calcium Oxalate Crystal Deposition in Rat Kidneys J. Am. Soc. Nephrol., March 1, 2004; 15(3): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Laverman, G. Remuzzi, and P. Ruggenenti ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S64 - 70. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, R. J. Hogg, R. D. Perrone, J. Lau, and G. Eknoyan National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification Ann Intern Med, July 15, 2003; 139(2): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hogg, S. Furth, K. V. Lemley, R. Portman, G. J. Schwartz, J. Coresh, E. Balk, J. Lau, A. Levin, A. T. Kausz, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification, and Stratification Pediatrics, June 1, 2003; 111(6): 1416 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Levinsky Specialist Evaluation in Chronic Kidney Disease: Too Little, Too Late Ann Intern Med, September 17, 2002; 137(6): 542 - 543. [Full Text] [PDF]
|
|
Article
